ICON Continues Asia-Pacific Expansion with New Office in Manila, Philippines
16 Março 2010 - 7:39AM
Business Wire
ICON plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced that
it will expand its footprint in Asia-Pacific with the opening of an
office in Manila, Philippines. This announcement follows the recent
expansion of ICON’s operations in Seoul, Korea and ICON Central
Laboratories’ move to a larger laboratory facility in
Singapore.
“With over 800 employees in 14 Asia-Pac countries and 13 years
of successful operations in the region, Asia-Pacific is a key
market for ICON,” commented Peter Gray, CEO at ICON. “Philippines’
large population, coupled with the country’s well-established
network of hospitals, physicians and investigators has made it an
attractive location for our clients, and one which we have
supported for a number of years through home-based employees.
Investing in local support and infrastructure through the office in
Manila will ensure that we can support future client demand as they
increasingly look to include Asia in their drug development
programs.”
ICON has conducted a wide range of clinical studies across all
therapeutic areas in Asia-Pacific, and has particular expertise in
managing oncology, cardiovascular, CNS and metabolic disorder
trials in the region. Current studies range from small local trials
to pan-Asia-Pacific and large global programs and are supported by
two fully-owned ICON central laboratories, strategically located in
Singapore and Bangalore, India. ICON has a presence in 14 countries
within the region – Australia, China, Hong Kong, India, Indonesia,
Japan, Korea, Malaysia, New Zealand, Philippines, Singapore,
Taiwan, Thailand and Vietnam.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has around 7,100 employees, operating from 68 locations in 38
countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024